false 0000748592 0000748592 2024-09-24 2024-09-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 24, 2024

 

Eterna Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-11460   31-1103425

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1035 Cambridge Street, Suite 18A    
Cambridge, MA   02141
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (212) 582-1199

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.005 per share   ERNA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01Entry into a Material Definitive Agreement.

 

On September 24, 2024, Eterna Therapeutics Inc. (the “Company,” “we,” “us,” or “our”), entered into an Exclusive License and Collaboration Agreement (“the L&C Agreement”), effective as of September 9, 2024, with Factor Bioscience Limited (“Factor”). The L&C Agreement terminated the Exclusive Amended and Restated License Agreement (the “A&R License Agreement”) entered into with Factor on November 14, 2023 as well as the exclusive license agreement that Dilos Bio (fka Exacis Biotherapeutics Inc. (“Exacis”)) entered into with Factor on November 4, 2020, which the Company acquired pursuant to an asset purchase agreement with Exacis and certain stockholders of Exacis on April 26, 2023 (the “Purchased License”).

 

Under the L&C Agreement, the Company has obtained an exclusive license in the fields of cancer, autoimmune disorders, and rare diseases with respect to certain licensed technology and has the right to develop the licensed technology directly or enter into co-development agreements with partners who can help bring such technology to market. The L&C Agreement also provides for certain services and materials to be provided by Factor to facilitate the development of the licensed technology and to enable the Company to scale up production at third party facilities.

 

The initial term of the L&C Agreement is one year after the effective date, and it automatically renews yearly thereafter. The Company may terminate the L&C Agreement for any reason upon 90 days’ written notice to Factor, and the parties otherwise have customary termination rights, including in connection with certain uncured material breaches and specified bankruptcy events.

 

Pursuant to the L&C Agreement, the Company will pay Factor $208,333 per month for the first twelve months, $50,000 per month for the first nine months toward patent costs, certain milestone payments, royalty payments on net sales of commercialized products and sublicensing fee payments.

 

The foregoing description of the L&C Agreement is only a summary and is qualified in its entirety by reference to the full text of the L&C Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

 

Item 1.02Termination of a Material Definitive Agreement.

 

The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the A&R License Agreement and the Purchased License is hereby incorporated by reference in response to this Item 1.02.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

-2-
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Eterna Therapeutics Inc.
   
Dated: September 27, 2024 By: /s/ Sanjeev Luther
   

Sanjeev Luther

    President and Chief Executive Officer

 

-3-

 

 

 

v3.24.3
Cover
Sep. 24, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 24, 2024
Entity File Number 001-11460
Entity Registrant Name Eterna Therapeutics Inc.
Entity Central Index Key 0000748592
Entity Tax Identification Number 31-1103425
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1035 Cambridge Street
Entity Address, Address Line Two Suite 18A
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code (212)
Local Phone Number 582-1199
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.005 per share
Trading Symbol ERNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Eterna Therapeutics Charts.
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Eterna Therapeutics Charts.